• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Wednesday, April 22, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

West Virginia University first to launch clinical trial utilizing non-opioid micropellet

Bioengineer by Bioengineer
November 15, 2018
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Photo courtesy of Sollis Corp.

MORGANTOWN, W.Va. – As part of an ongoing commitment to battle opioid addiction, the Rockefeller Neuroscience Institute (RNI) at West Virginia University today (Nov. 15) marked a major milestone, enrolling the first patient in a randomized clinical trial that will test the effectiveness of an injectable non-opioid, non-steroid micropellet to treat sciatica.

The phase III clinical trial utilizes a clonidine micropellet, which is half the size of a grain of rice and is placed in a patient's lower back to combat sciatica pain for up to one year. The procedure was successfully completed this afternoon.

"Innovative technologies that act directly at a target location like this micropellet are crucial to reducing the need for systemic medications and opioids for chronic pain," Ali Rezai, M.D., executive chair of the Rockefeller Neuroscience Institute, said. "Our hope is that we can look back on this day and say we made a significant advance in the ongoing efforts to treat chronic pain and combat the opioid crisis."

Dr. Rezai is not directly involved in the trial as he serves as a scientific advisor to Sollis Therapeutics, the Ohio-based interventional pain company developing the micropellet.

With more than five million people in the U.S. affected by sciatica – one of the most common causes of back and leg pain – the Sollis micropellet can potentially provide patients with a pain-relief solution and an alternative to addictive opioid pain medications. Unfortunately, in many cases, currently available treatment options for the pain management of sciatica and other back pain have inadvertently led to opioid abuse.

"Having the opportunity to investigate new non-opioid treatments for sciatica and a range of pain conditions is directly aligned with the WVU Medicine Center for Integrative Pain Management's mission to combat the opioid crisis in West Virginia and nationwide," Richard Vaglienti, M.D., principal investigator and director of the Center for Integrative Pain Management, said.

"Our doctors and researchers at the Rockefeller Neuroscience Institute continue to do amazing things that will help make all of our lives better," President Gordon Gee said. "This kind of ground-breaking research would not be possible without the assistance of many people, including Gov. Jim Justice, Rep. David McKinley, and Senators Shelley Moore Capito and Joe Manchin, all of whom have been fully supportive of these initiatives."

In West Virginia, where the number of opioid-related deaths is on course to set a record for overdose deaths this year, the micropellet procedure – if successful – could one day be a game-changer.

"Knowing that even a single day of opioid usage is associated with a probability that the patient will be taking opioids a year later underscores the need for innovations like ours to impact the opioid crisis," Gregory Fiore, M.D., president and CEO of Sollis Therapeutics, said. "We are pleased to team up with the researchers at the WVU RNI and other sites nationwide."

###

Additional patients are expected to participate in the study at WVU. To see if you or a family member might be eligible, please contact Angela Pugh by emailing [email protected] or calling 304-293-6780.

The West Virginia University Rockefeller Neuroscience Institute is a global leader in the discovery, development, and delivery of world-class research in human performance and brain health. It includes the clinical, research, and academic missions of the WVU Departments of Neurosurgery, Neurology, and Behavioral Medicine and Psychiatry, as well as several other academic departments across the university. The Institute spearheads efforts to develop innovative solutions for West Virginians and those across the world with neurological and psychiatric conditions ranging from Alzheimer's to Parkinson's; autism to stroke; and paralysis to chronic pain, addiction, and traumatic brain injury. For more information on the WVU Rockefeller Neuroscience Institute, visit wvumedicine.org/RNI.

Media Contact

Anthony Condia
[email protected]
304-285-7275

http://www.wvuh.edu

Original Source

https://wvumedicine.org/news/article/west-virginia-university-first-site-to-launch-clinical-trial-utilizing-non-opioid-micropellet-implan/

Share12Tweet8Share2ShareShareShare2

Related Posts

UCT Researchers Identify Molecular “Switch” Driving Cancer Progression

UCT Researchers Identify Molecular “Switch” Driving Cancer Progression

April 22, 2026
Decoding the Genetic Origins of Indigenous Peoples

Decoding the Genetic Origins of Indigenous Peoples

April 22, 2026

How Cells Convert Mechanical Forces into Biochemical Signals

April 22, 2026

Unraveling Mitochondrial Genomic Factors Behind Impaired Bone Healing in Aging

April 22, 2026
Please login to join discussion

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    799 shares
    Share 320 Tweet 200
  • Scientists Investigate Possible Connection Between COVID-19 and Increased Lung Cancer Risk

    65 shares
    Share 26 Tweet 16
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    59 shares
    Share 24 Tweet 15
  • NSF funds machine-learning research at UNO and UNL to study energy requirements of walking in older adults

    101 shares
    Share 40 Tweet 25

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Study Reveals Gut Microbiome as Key Predictor of IBS Treatment Response

Study Finds Patients Experiencing Greater Marginalization More Likely to Use Emergency Departments for Concussion Care

Geoengineering Offers New Hope for Safeguarding the Amazon Rainforest Against Climate Change

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 80 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.